Your browser is no longer supported. Please, upgrade your browser.
Settings
AKRO Akero Therapeutics, Inc. daily Stock Chart
AKRO [NASD]
Akero Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.30 Insider Own2.40% Shs Outstand28.18M Perf Week-0.25%
Market Cap568.67M Forward P/E- EPS next Y-2.28 Insider Trans- Shs Float27.84M Perf Month5.71%
Income-89.80M PEG- EPS next Q-0.59 Inst Own78.30% Short Float1.64% Perf Quarter-1.94%
Sales- P/S- EPS this Y- Inst Trans0.04% Short Ratio3.28 Perf Half Y-2.89%
Book/sh5.12 P/B3.94 EPS next Y15.20% ROA-77.70% Target Price32.00 Perf Year-
Cash/sh5.24 P/C3.85 EPS next 5Y- ROE-182.60% 52W Range16.06 - 34.00 Perf YTD-9.08%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.65% Beta-
Dividend %- Quick Ratio22.30 Sales past 5Y- Gross Margin- 52W Low25.65% ATR1.86
Employees10 Current Ratio22.30 Sales Q/Q- Oper. Margin- RSI (14)48.31 Volatility3.33% 10.12%
OptionableNo Debt/Eq0.00 EPS Q/Q27.00% Profit Margin- Rel Volume0.86 Prev Close19.69
ShortableYes LT Debt/Eq0.00 EarningsNov 11 Payout- Avg Volume139.11K Price20.18
Recom1.70 SMA20-2.89% SMA50-2.01% SMA200-6.90% Volume120,240 Change2.49%
Jul-15-19Initiated ROTH Capital Buy $34
Jul-15-19Initiated JP Morgan Overweight $28
Jul-15-19Initiated Jefferies Buy $28
Jul-15-19Initiated Evercore ISI Outperform $35
Jan-13-20 08:00AM  Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients PR Newswire
Jan-08-20 04:05PM  Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference PR Newswire
Dec-19-19 05:51PM  4 More Biotechs With Blockbuster Potential GuruFocus.com
Dec-16-19 04:05PM  Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH PR Newswire -7.78%
Dec-14-19 07:22PM  Hedge Funds Are Dumping Akero Therapeutics, Inc. (AKRO) Insider Monkey
Nov-13-19 04:01PM  Akero Therapeutics to Present at the Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 07:00AM  Akero Therapeutics Reports Recent Highlights and Third Quarter 2019 Financial Results PR Newswire
Nov-04-19 08:00AM  InSphero Wins Sino-European Innovation Award for Breakthrough NASH Discovery and Safety Testing Platform PR Newswire -5.34%
Oct-31-19 02:07PM  Hedge Funds Have Never Been This Bullish On Akero Therapeutics, Inc. (AKRO) Insider Monkey
Sep-19-19 06:54AM  Does Akero Therapeutics, Inc. (NASDAQ:AKRO) Need To Raise More Cash? Simply Wall St. -5.21%
Sep-04-19 07:00AM  Akero Therapeutics To Present At The Morgan Stanley 17th Annual Global Healthcare Conference PR Newswire
Aug-12-19 07:00AM  Akero Therapeutics Reports Recent Highlights and Second Quarter 2019 Financial Results PR Newswire
Jul-09-19 10:07AM  How this Peninsula biotech plans to turn a $100 million round into 'next generation' of cancer drugs American City Business Journals
Jul-03-19 07:31AM  The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief Benzinga
Jul-02-19 04:05PM  Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED) PR Newswire
Jun-24-19 04:05PM  Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-20-19 11:44AM  Akero Therapeutics IPO Opens Above IPO Price Benzinga
Jun-19-19 09:20PM  Akero Therapeutics Announces Pricing of Initial Public Offering PR Newswire
Jun-18-19 12:10PM  Akero Therapeutics IPO: What You Need To Know Benzinga
Jun-17-19 10:07AM  IPO Outlook For The Week: Biotechs And A Grocery Outlet Benzinga
Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.